MCL1 and ovarian carcinoma: Our results suggest that the pre-formed BAK/MCL1 complexes not only correlate with sensitivity to paclitaxel and S63845 in ovarian cancer cells but also predict synergy of the paclitaxel/S63845 combination (Fig. 6).